ArticleInterface focus2011
Clinically driven design of multi-scale cancer models: the ContraCancrum project paradigm.
Article in Interface focus, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics.Frontiers in oncology · 2021Review
- High-throughput binding affinity calculations at extreme scales.BMC bioinformatics · 2018Article
- A study on the predictability of acute lymphoblastic leukaemia response to treatment using a hybrid oncosimulator.Interface focus · 2018Article
- Clinical implications of in silico mathematical modeling for glioblastoma: a critical review.Journal of neuro-oncology · 2018Review
- E-Science technologies in a workflow for personalized medicine using cancer screening as a case study.Journal of the American Medical Informatics Association : JAMIA · 2017Article
- In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model.PLoS computational biology · 2016Article
- Differentiation resistance through altered retinoblastoma protein function in acute lymphoblastic leukemia: in silico modeling of the deregulations in the G1/S restriction point pathway.BMC systems biology · 2016Article
- Semantic biomedical resource discovery: a Natural Language Processing framework.BMC medical informatics and decision making · 2015Article
- Integrated PK-PD and agent-based modeling in oncology.Journal of pharmacokinetics and pharmacodynamics · 2015Review
- Integrating Multiscale Modeling with Drug Effects for Cancer Treatment.Cancer informatics · 2015Review
- The standardized histogram shift of t2 magnetic resonance image (MRI) signal intensities of nephroblastoma does not predict histopathological diagnostic information.Cancer informatics · 2015Article
- Simulating radiotherapy effect in high-grade glioma by using diffusive modeling and brain atlases.Journal of biomedicine & biotechnology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The challenge of modelling cancer presents a major opportunity to improve our ability to reduce mortality from malignant neoplasms, improve treatments and meet the demands associated with the individualization of care needs. This is the central motivation behind the ContraCancrum project. By developing integrated multi-scale cancer models, ContraCancrum is expected to contribute to the advancement of in silico oncology through the optimization of cancer treatment in the patient-individualized context by simulating the response to various therapeutic regimens. The aim of the present paper is to describe a novel paradigm for designing clinically driven multi-scale cancer modelling by bringing together basic science and information technology modules. In addition, the integration of the multi-scale tumour modelling components has led to novel concepts of personalized clinical decision support in the context of predictive oncology, as is also discussed in the paper. Since clinical adaptation is an inelastic prerequisite, a long-term clinical adaptation procedure of the models has been initiated for two tumour types, namely non-small cell lung cancer and glioblastoma multiforme; its current status is briefly summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.